What is the 13F Pro Quality Score for ANIX?

13F Pro ranks Anixa Biosciences Inc (ANIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANIX's current score at https://13fpro.ai/research/ANIX (free sign-up required for the full ranking).

Where does 13F Pro source ANIX data?

All Anixa Biosciences Inc fundamentals and ownership data come directly from SEC EDGAR. Anixa Biosciences Inc files with the SEC under CIK 715446. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANIX in?

Anixa Biosciences Inc (ANIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANIX research updated on 13F Pro?

ANIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Anixa Biosciences Inc(ANIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 715446 ANIX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $9.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ANIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Anixa Biosciences Inc (ANIX), a Healthcare sector company. ANIX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $9.3m in revenue. Based on the latest XBRL financial filings (Q2 2026), Anixa Biosciences Inc reports net income of $-2.5M, free cash flow of $-1.7M. Top institutional holders of ANIX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Laird Norton Wetherby Company,, UBS Group AG, based on the most recent SEC filings. ANIX trades on the Nasdaq exchange and files with the SEC under CIK 715446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anixa Biosciences Inc directly from SEC EDGAR.

Net Income

Q2 2026

$-2.5M

Free Cash Flow

Q2 2026

$-1.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $512.0KFY23 $210.0KFY24 $210.0KFY25 —

Net Income

+13.0% YoY

$-10.9MFY 2025

FY21 $-13.0MFY23 $-9.8MFY24 $-12.6MFY25 $-10.9M

Operating Income

+15.4% YoY

$-11.7MFY 2025

FY21 $-13.1MFY23 $-11.0MFY24 $-13.8MFY25 $-11.7M

EPS (Diluted)

+12.8% YoY

$-0.34FY 2025

FY21 —FY23 $-0.32FY24 $-0.39FY25 $-0.34

Total Assets

-25.5% YoY

$16.1MFY 2025

FY21 $36.3MFY23 $25.5MFY24 $21.6MFY25 $16.1M

Op. Cash Flow

+2.2% YoY

$-7.2MFY 2025

FY21 $-4.9MFY23 $-6.2MFY24 $-7.3MFY25 $-7.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	—	$210.0K +0.0%	$210.0K -59.0%	$512.0K	—	$250.0K
Net Income	$-10.9M +13.0%	$-12.6M -28.0%	$-9.8M +24.3%	$-13.0M -29.3%	$-10.0M +14.0%	$-11.6M
Operating Income	$-11.7M +15.4%	$-13.8M -25.6%	$-11.0M +16.2%	$-13.1M -31.6%	$-10.0M +16.1%	$-11.9M
EPS (Diluted)	$-0.34 +12.8%	$-0.39 -21.9%	$-0.32	—	—	—
Total Assets	$16.1M -25.5%	$21.6M -15.4%	$25.5M -29.6%	$36.3M +283.6%	$9.5M +50.2%	$6.3M
Operating Cash Flow	$-7.2M +2.2%	$-7.3M -18.1%	$-6.2M -25.7%	$-4.9M +20.0%	$-6.2M -30.2%	$-4.7M

AI Insight: ANIX Financial Trends

Pre-revenue biotech burning cash steadily with equity base shrinking 36% since Q3 2024; no inflection visible.

• Net income and operating income stable at $-3M per quarter; operating cash burn fluctuating $-1M to $-3M with no clear improvement trajectory.

• Equity declined from $22M in Q3 2024 to $14M in Q2 2026, a 36% contraction driven by ongoing losses and no revenue generation.

⚠ Equity base at $14M is critically low; continued $2–3M quarterly losses leave runway <2 years without financing or revenue milestone.

⚠ No revenue reported across all eight quarters; pipeline advancement or clinical trial progress data needed to validate commercialization path.

AI Insight: ANIX Ratio Trends

Anixa remains deeply unprofitable with no operating margin data available; ROIC has oscillated between –58.7% and –75.9% over the past 18 months with no clear improvement trajectory.

• ROE and ROIC both deteriorated from Q3 2025 (–54.4% and –58.7% respectively) to Q4 2025 (–71.1% and –75.9%), erasing three quarters of gains.

• Latest quarter (Q2 2026) shows ROA of –67.7% and ROIC of –73.2%, consistent with the prior 18-month average; no sustained improvement visible.

⚠ Q3 2025 marked a brief inflection point with ROIC reaching –58.7%, the best level in the dataset, but gains reversed immediately in Q4 2025.

⚠ Operating and net profit margins remain unmeasurable (all dashes), indicating ongoing losses mask underlying operational performance.

Get alerted when ANIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Anixa Biosciences Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANIX

VANGUARD CAPITAL MANAGEMENT LLC
$3.4M1,314,982 sh
Laird Norton Wetherby Trust Company, LLC
$1.5M566,327 sh
UBS Group AG
$1.4M551,637 sh
D.A. DAVIDSON & CO.
$1.4M539,272 sh
GEODE CAPITAL MANAGEMENT, LLC
$941.4K364,731 sh
VANGUARD FIDUCIARY TRUST CO
$493.0K191,074 sh
MARSHALL WACE, LLP
$446.8K173,179 sh
BlackRock, Inc.
$438.9K170,103 sh
STATE STREET CORP
$410.3K159,040 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$256.6K99,468 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$3.4M	1,314,982
Laird Norton Wetherby Trust Company, LLC	$1.5M	566,327
UBS Group AG	$1.4M	551,637
D.A. DAVIDSON & CO.	$1.4M	539,272
GEODE CAPITAL MANAGEMENT, LLC	$941.4K	364,731
VANGUARD FIDUCIARY TRUST CO	$493.0K	191,074
MARSHALL WACE, LLP	$446.8K	173,179
BlackRock, Inc.	$438.9K	170,103
STATE STREET CORP	$410.3K	159,040
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$256.6K	99,468

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANIX on your watchlist

Track score changes the day Anixa Biosciences Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANIX a good stock to buy?

13F Pro's AI-powered analysis of Anixa Biosciences Inc (ANIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANIX are available on the ANIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anixa Biosciences Inc's investment landscape.